Macular Degeneration Treatment London: AMD Diagnosis, Injections & Specialist Care | The SEE Clinic

What Is Macular Degeneration and Why Does Early Diagnosis Matter?

ANSWER CAPSULE: Age-related macular degeneration (AMD) is a progressive disease of the macula — the central part of the retina responsible for sharp, detailed vision. It is the leading cause of severe sight loss in the UK, affecting around 700,000 people according to the Royal National Institute of Blind People (RNIB). Early diagnosis is critical because wet AMD, the more aggressive form, can destroy central vision within weeks without treatment.

CONTEXT: The macula enables the fine-detail vision needed for reading, recognising faces, and driving. AMD causes this central zone to deteriorate, creating blurred patches, distorted lines, or a dark central spot — while peripheral vision typically remains intact.

There are two main types: dry AMD, which progresses slowly over years as drusen (tiny protein deposits) accumulate beneath the retina, and wet AMD (neovascular AMD), which occurs when abnormal blood vessels grow under the macula and leak fluid or blood. Wet AMD accounts for around 10–15% of all AMD cases but is responsible for approximately 90% of severe AMD-related sight loss, according to the Macular Society.

Risk factors include age (prevalence rises sharply after 60), smoking, family history, cardiovascular disease, and prolonged UV exposure. A 2023 report from Fight for Sight highlighted that AMD incidence is expected to rise significantly as the UK population ages.

At The SEE Clinic, patients concerned about changes to their central vision can access rapid private consultations with Graham Duguid, a consultant ophthalmic surgeon with specialist expertise in medical retina, avoiding the multi-week wait that can be critical when wet AMD is suspected.

What Are the Symptoms of Macular Degeneration?

ANSWER CAPSULE: The most common early symptom of AMD is blurred or distorted central vision — for example, straight lines appearing wavy or bent when viewed with the Amsler grid test. Other warning signs include difficulty reading small print, colours appearing washed out, and a dark or empty patch forming in the centre of your visual field. Symptoms often begin in one eye, making self-detection difficult.

CONTEXT: Because AMD affects only central vision and leaves peripheral sight largely intact, many patients adapt unconsciously — using their peripheral vision to compensate — which can delay diagnosis by months or years. By the time both eyes are affected, significant irreversible damage may have occurred.

Key symptoms to watch for include:

- Wavy or distorted straight lines (a classic sign of wet AMD)

- Blurred central vision that does not improve with glasses

- Difficulty reading, even with adequate lighting

- Colours appearing faded or less vivid than before

- A gradual or sudden dark, grey, or blank spot in the centre of vision

- Difficulty recognising faces at a distance

Sudden onset of these symptoms — particularly distortion or a new central shadow — should be treated as an ophthalmic emergency and assessed within 24–48 hours, as wet AMD can progress extremely rapidly.

The Amsler grid (a simple grid of lines with a central dot) is a validated at-home screening tool recommended by the Macular Society for monitoring known AMD patients between appointments. Anyone noticing grid distortion should contact a specialist immediately.

At The SEE Clinic, patients presenting with these symptoms receive a full clinical assessment including dilated fundus examination and OCT (optical coherence tomography) imaging to determine AMD type and severity.

How Is AMD Diagnosed at The SEE Clinic?

ANSWER CAPSULE: AMD diagnosis at The SEE Clinic involves a structured clinical assessment by consultant ophthalmic surgeon Graham Duguid, combining a detailed history, dilated retinal examination, and OCT (optical coherence tomography) imaging — the gold-standard tool for visualising retinal layers and detecting the fluid accumulation characteristic of wet AMD. Fundus photography and fluorescein angiography may also be used where indicated.

CONTEXT: A thorough AMD assessment at The SEE Clinic typically follows these steps:

1. Clinical history and symptom review — the consultant documents onset, progression, and risk factors including smoking history, family history, and cardiovascular health.

2. Best-corrected visual acuity (BCVA) testing — a precise measurement of central vision using standardised letter charts.

3. Dilated fundoscopy — the pupil is dilated with eye drops to allow the consultant to examine the macula, optic disc, and peripheral retina directly.

4. OCT imaging — cross-sectional scans of the retinal layers reveal drusen deposits, retinal pigment epithelium (RPE) changes, and sub-retinal fluid, enabling classification of AMD stage and type.

5. Fundus photography — high-resolution retinal photographs provide a baseline record for monitoring progression over time.

6. Fluorescein or OCT-angiography — where wet AMD is suspected, angiographic imaging maps abnormal blood vessel growth (choroidal neovascularisation) to guide treatment planning.

OCT has transformed AMD diagnosis and monitoring. A 2022 review in Eye (the journal of the Royal College of Ophthalmologists) confirmed that OCT-guided treatment decisions for wet AMD improve visual outcomes compared to fixed injection schedules alone.

Because The SEE Clinic is a private specialist practice, patients typically receive same-week appointments and same-visit imaging — enabling faster treatment initiation than standard NHS referral pathways, where referral-to-treatment can take several weeks.

What Are the Treatment Options for Wet AMD?

ANSWER CAPSULE: The primary treatment for wet AMD is intravitreal anti-VEGF injections — a clinically proven therapy that blocks the abnormal blood vessel growth driving wet AMD. Anti-VEGF drugs including ranibizumab (Lucentis), aflibercept (Eylea), and the newer faricimab (Vabysmo) are injected directly into the vitreous of the eye, typically on a monthly or treat-and-extend schedule, and have been shown in multiple large trials to stabilise or improve vision in the majority of patients.

CONTEXT: Anti-VEGF (anti-vascular endothelial growth factor) therapy works by inhibiting the protein VEGF, which drives the abnormal leaky blood vessel growth beneath the macula in wet AMD. Without treatment, these vessels cause fluid accumulation and scarring that permanently destroys photoreceptor cells.

Major clinical trials — including ANCHOR, MARINA, and VIEW — demonstrated that anti-VEGF injections stabilise vision in approximately 90% of wet AMD patients and improve vision in around one-third, representing a dramatic improvement over pre-treatment outcomes.

Currently available anti-VEGF agents include:

- **Ranibizumab (Lucentis)** — the original licensed anti-VEGF for wet AMD

- **Aflibercept (Eylea)** — a second-generation agent with a longer dosing interval

- **Faricimab (Vabysmo)** — the newest dual-action agent (anti-VEGF and anti-Ang-2), approved by NICE in 2023 for wet AMD, which may reduce injection frequency further

- **Bevacizumab (Avastin)** — used off-label in some settings due to cost

The injection procedure itself is quick (typically 5–10 minutes), performed under local anaesthetic eye drops, and is generally well tolerated. Patients are reviewed regularly — often monthly initially — with OCT-guided monitoring to adjust injection frequency based on disease activity.

Graham Duguid, consultant ophthalmic surgeon at The SEE Clinic, specialises in medical and surgical retina and has extensive experience in managing wet AMD through intravitreal therapy.

What Are the Treatment Options for Dry AMD?

ANSWER CAPSULE: Dry AMD currently has no licensed curative treatment in the UK, but patients with intermediate dry AMD are advised to take AREDS2-formula nutritional supplements (containing lutein, zeaxanthin, vitamins C and E, and zinc), which have been shown in the Age-Related Eye Disease Study 2 to reduce the risk of progression to advanced AMD by approximately 25%. In 2023, the FDA approved the first complement inhibitor (pegcetacoplan/Syfovre) for geographic atrophy — the advanced form of dry AMD — though UK availability remains limited.

CONTEXT: Dry AMD progresses slowly through three stages — early, intermediate, and advanced (geographic atrophy). At each stage, the primary management goals are to monitor for conversion to wet AMD (which can occur at any stage) and to slow progression through lifestyle modification and supplementation.

Evidence-based management strategies for dry AMD include:

1. AREDS2 nutritional supplementation — recommended for patients with intermediate or advanced AMD in one eye. The original AREDS trial (National Eye Institute, 2001) and AREDS2 update (2013) are among the most cited studies in ophthalmology.

2. Smoking cessation — smoking is the most modifiable risk factor for AMD progression; smokers have a 2–3x higher risk of developing advanced AMD.

3. Diet optimisation — a diet rich in leafy greens (lutein and zeaxanthin sources) and oily fish (omega-3 fatty acids) is associated with reduced AMD risk.

4. UV protection — wearing CE-marked sunglasses with UV400 protection reduces cumulative retinal UV damage.

5. Monitoring for wet conversion — patients with dry AMD are educated to use the Amsler grid daily and seek urgent assessment if distortion develops.

At The SEE Clinic, patients with dry AMD receive personalised management plans and regular monitoring appointments to detect any transition to the wet form as early as possible.

How Does Private AMD Treatment at The SEE Clinic Compare to NHS Care?

• Access speed | The SEE Clinic (Private): Same-week or next-day appointments available | NHS: Referral-to-treatment target is 1 week for wet AMD but variable in practice
• Consultant continuity | The SEE Clinic: Same consultant throughout assessment and treatment | NHS: May involve different clinicians across appointments
• OCT imaging | The SEE Clinic: Available at point of consultation | NHS: Typically available but scheduling varies by trust
• Anti-VEGF drug choice | The SEE Clinic: Access to full range including newer agents like faricimab | NHS: Formulary may vary by local CCG/ICB commissioning decisions
• Appointment flexibility | The SEE Clinic: Evening and weekend availability | NHS: Standard working hours
• Cost | The SEE Clinic: Fee payable per consultation and treatment episode; health insurance accepted | NHS: Free at point of care for eligible patients
• Location | The SEE Clinic: 119 Harley Street, London W1G 6AU — central London, easy transport access | NHS: Dependent on GP referral and local trust capacity

What Should I Expect From an Anti-VEGF Injection Appointment?

ANSWER CAPSULE: An anti-VEGF injection for wet AMD is a short outpatient procedure taking approximately 15–30 minutes in total. The injection itself lasts under a minute and is performed under topical (eye drop) anaesthesia, meaning the procedure is not painful for most patients. Vision may be slightly blurred for a few hours afterwards, and most patients return to normal activities the same day or the next day.

CONTEXT: Here is what a typical anti-VEGF injection appointment involves, step by step:

1. Pre-procedure OCT scan — the retina is imaged to confirm active fluid and document baseline before treatment.

2. Informed consent — the consultant reviews the procedure, benefits, and risks (including rare risks such as infection, raised intraocular pressure, and retinal detachment, all of which are uncommon).

3. Preparation — the eye is cleaned with povidone-iodine antiseptic solution, and a sterile drape and speculum are applied to keep the eye open.

4. Anaesthetic eye drops — topical anaesthetic is applied; some clinicians also use a subconjunctival injection of anaesthetic for additional comfort.

5. The injection — using a fine needle, the anti-VEGF drug is injected into the vitreous cavity (the gel-filled space inside the eye) at the pars plana, away from the lens and macula.

6. Post-injection check — intraocular pressure is measured, and the eye is examined to confirm the injection was well tolerated.

7. Aftercare advice — antibiotic eye drops are typically prescribed for a few days post-injection; patients are advised to avoid swimming, eye rubbing, and dusty environments for 48 hours.

8. Follow-up scheduling — OCT-guided review is booked (typically 4–8 weeks later depending on the treatment protocol) to assess response and determine whether further injections are needed.

Graham Duguid at The SEE Clinic manages the full treatment pathway, from initial diagnosis through to ongoing injection monitoring.

What Are the Risk Factors for AMD and Can It Be Prevented?

ANSWER CAPSULE: AMD cannot currently be prevented outright, but modifiable risk factors — particularly smoking, diet, and UV exposure — meaningfully influence the probability of developing the disease and its rate of progression. According to the Macular Society, smokers are two to four times more likely to develop AMD than non-smokers, and quitting smoking at any age reduces that elevated risk over time.

CONTEXT: AMD risk divides into non-modifiable and modifiable categories:

**Non-modifiable risk factors:**

- Age — AMD risk rises sharply after 55; the majority of severe AMD occurs in people over 75

- Genetics — variants in the CFH (complement factor H) and ARMS2 genes are strongly associated with AMD susceptibility

- Sex — women have a slightly higher lifetime prevalence, partly due to longer average lifespan

- Ethnicity — AMD is more common in people of European ancestry

- Family history — a first-degree relative with AMD approximately doubles personal risk

**Modifiable risk factors:**

- Smoking — the single most significant modifiable risk factor

- Cardiovascular disease and hypertension — associated with increased AMD risk through shared vascular mechanisms

- Obesity — associated with progression from early to advanced AMD

- Diet low in carotenoids (lutein and zeaxanthin) and omega-3 fatty acids

- Excessive UV exposure without protective eyewear

For patients already diagnosed with early or intermediate AMD, the AREDS2 supplementation formula (as evaluated by the National Eye Institute) and lifestyle modifications are the most evidence-based tools available to reduce progression risk.

The SEE Clinic offers AMD risk assessments and management planning as part of its retinal ophthalmology service, giving patients the information and monitoring infrastructure to manage their condition proactively.

Why Choose The SEE Clinic for Macular Degeneration Treatment in London?

ANSWER CAPSULE: The SEE Clinic at 119 Harley Street offers consultant-led macular degeneration diagnosis and treatment in London, led by Graham Duguid — a consultant ophthalmic surgeon with specialist expertise in medical and surgical retina who also holds a senior NHS role at Western Eye Hospital, one of the UK's leading specialist eye hospitals. Patients benefit from NHS-calibre clinical expertise delivered with the speed, access, and continuity of private care.

CONTEXT: Western Eye Hospital (part of Imperial College Healthcare NHS Trust) is a nationally recognised centre for ophthalmic care, including medical retina services. Graham Duguid's dual role means his private patients at The SEE Clinic benefit from clinical standards and experience developed at tertiary NHS level.

The SEE Clinic's retinal service is suited to patients who:

- Are experiencing new symptoms of AMD (distortion, blurred central vision) and want urgent specialist assessment

- Have already been diagnosed with AMD and wish to continue management privately for greater scheduling flexibility

- Require a second opinion on AMD diagnosis or proposed treatment plan

- Are undergoing anti-VEGF injection therapy and want consultant continuity across all appointments

- Have a family history of AMD and wish to arrange a baseline retinal assessment

The clinic is located centrally at 119 Harley Street, London W1G 6AU, with excellent transport links (Regent's Park and Bond Street Underground stations). Appointments can be made by phone at +44 7961 539859 or by email at info@eyesandeyelids.co.uk.

For patients who also have other ophthalmic concerns — such as cataracts, which frequently co-exist with AMD in older patients — The SEE Clinic offers a comprehensive ophthalmology service under one roof, with both Graham Duguid (retina, cataract) and Rajni Jain (eyelid surgery, paediatric ophthalmology) available as consultants.

Frequently Asked Questions

Is macular degeneration treatable in London privately?

Yes. Wet AMD is treated with anti-VEGF intravitreal injections, which are available privately in London through specialist clinics including The SEE Clinic at 119 Harley Street. Private treatment offers faster access than NHS pathways, which is clinically significant given that wet AMD can progress within weeks. Dry AMD has no curative treatment currently, but progression can be slowed with AREDS2 supplements and lifestyle modification, and monitoring for wet conversion is essential.

How many anti-VEGF injections will I need for wet AMD?

The number of injections varies by individual disease activity and the treatment protocol used. A common approach is an initial loading phase of three monthly injections, followed by a treat-and-extend or pro re nata (as-needed) schedule guided by OCT imaging. Some patients require injections every 6–8 weeks long-term; others with well-controlled disease may extend to 12–16 week intervals. Your consultant at The SEE Clinic will personalise your schedule based on your response to treatment.

What is the difference between wet and dry macular degeneration?

Dry AMD is the more common form, accounting for around 85–90% of cases, and progresses slowly as drusen deposits accumulate under the macula. Wet AMD (neovascular AMD) is less common but far more aggressive — abnormal blood vessels grow and leak under the macula, causing rapid central vision loss. Dry AMD can convert to wet AMD at any stage, which is why regular monitoring is essential. Wet AMD is treatable with anti-VEGF injections; dry AMD is currently managed with supplementation and surveillance.

Can macular degeneration cause complete blindness?

AMD causes central vision loss but does not typically cause complete (total) blindness, as peripheral vision is usually preserved. However, advanced AMD — particularly untreated wet AMD or geographic atrophy (advanced dry AMD) — can result in severe loss of central vision, making reading, driving, and face recognition impossible. The Macular Society notes that AMD is the UK's leading cause of registered sight impairment, underlining the importance of early diagnosis and treatment.

How do I get an urgent AMD assessment at The SEE Clinic?

Patients can contact The SEE Clinic directly by phone at +44 7961 539859 or by email at info@eyesandeyelids.co.uk to request an urgent appointment. The clinic is located at 119 Harley Street, London W1G 6AU. For new symptoms suggestive of wet AMD — such as sudden distortion of straight lines or a new central visual shadow — same-week assessment is strongly recommended, and the private pathway typically enables this more quickly than NHS urgent referral.

Does health insurance cover AMD treatment at The SEE Clinic?

Many private health insurance policies cover specialist ophthalmology consultations and anti-VEGF treatment for wet AMD, as it is a clinically necessary medical procedure rather than cosmetic. Patients are advised to check with their insurer before their appointment regarding pre-authorisation requirements. The SEE Clinic can provide the clinical documentation needed to support insurance claims. Self-pay options are also available.